دزیمتری سطح پوست با استفاده از دزیمترهای ترمولومینسانس و مقایسه آن با سیستم‌های طراحی درمان در براکی‌تراپی سرطان رحم

[1] B. Chittenden, G. Fullerton, A Maheshwari and S. Bhattacharya. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review, Reprod Biomed Online. 19 (3), 398 (2009) 398-405. [2] R. Sankaranarayanan and J. Ferlay. Worldwide burden of gynaecological cancer:the size of the problem. Best Pract Res Clin Obstet Gynaeco. 20(2),207 (2006) 207-225. [3] G. Rieck and A. Fiander. The effect of lifestyle factors on gynaecological cancer, Best Pract Res Clin Obstet Gynaecol. 20 (2), 227(2006) 227-251. [4] M. Allahverdi, M. Sarkhosh M, M. Aghili, R. Jaberi, A. Adelnia and G. Geraily. Evaluation of treatment planning system of brachytherapy according to dose to the rectum delivered, Radiat Prot Dosim. 150 (3), 312(2011) 312-315. [5] S. Gholami, H.R. Mirzaei and A.J. Arfaee. Dose distribution verification for GYN brachytherapy using EBT Gafchromic film and TG-43 calculation, Rep Pract Oncol Radiother. 21 (5), 480(2016) 480-486. [6] S. Sahoo, T.P. Selvam, R. Vishwakarma and G. Chourasiya. Monte Carlo modeling of 60Co HDR brachytherapy source in water and in different solid water phantom materials, J Med Phys Assoc Med Physicists India. 35 (1), 15(2010) 15-22. [7] G. Anagnostopoulos, D. Baltas and A. Geretschlaeger. In vivo thermoluminescence dosimetry dose verification of transperineal 192Ir high-dose-rate brachytherapy using CT-based planning for the treatment of prostate cancer, Int J Radiat Oncol Biol Phys. 57 (4), 1183 (2003) 1183-1191. [8] B. Reniers, G. Landry, R. Eichner, A. Hallil and F. Verhaegen. In vivo dosimetry for gynaecological brachytherapy using a novel position sensitive radiation detector: feasibility study, Med Phys. 39(4), 1925(2012) 1925-1935. [9] J.A. Raffi, S.D. Davis and C.G. Hammer. Determination of exit skin dose for intracavitary accelerated partial breast irradiation with thermoluminescent dosimeters, Med Phys. 37(6), 2693(2010) 2693-2702. [10] C. Waldhäusl, A. Wambersie, R. Pötter and D. Georg. In-vivo dosimetry for gynaecological brachytherapy: physical and clinical considerations, Radiother Oncol . 77 (3), 310(2005) 310-317. [11] G. Kertzscher, A. Rosenfeld and S. Beddar. Tanderup K, Cygler J. In vivo dosimetry: trends and prospects for brachytherapy, British J Radiol, 87(1041), 206(2014) 02-06. [12] A. Haughey, G. Coalter and K. Mugabe. Evaluation of linear array MOSFET detectors for in vivo dosimetry to measure rectal dose in HDR brachytherapy, Australas Phys Eng Sci Med. 34 (3), 361(2011) 361-366. [13] A.S. Kirov, J.F. Williamson, A. Meigooni and Y. Zhu. TLD, diode and Monte Carlo dosimetry of an 192Ir source for high dose-rate brachytherapy, Phys Med Biol. 40 (12), 2015(1995) 2015-2036. [14] P.W. Grigsby, A. Georgiou, F Jeffrey and C.A. Perez. Anatomic variation of gynecologic brachytherapy prescription points, Int J Radiat Oncol Biol Phys. 27 (3), 725(1993) 1-5. [15] M.A. Mosleh-Shirazi, E. Shahcheraghi-Motlagh and M.H. Gholami. Influence of dwell time homogeneity error weight parameter on treatment plan quality in inverse optimized high-dose-rate cervix brachytherapy using SagiPlan, J Contemp Brachytherapy. 11 (3), 256(2019) 256-266. [16] M. Marvi, S. Gholami and M. Salehi Barough. Evaluation of exit skin dose for intra-cavitary brachytherapy treatments by the BEBIG 60Co machine using thermoluminescent dosimeters, Journal of Radiotherapy in Practice.1 (16), 1 (2020) 49-54. [17] C.N. Nomden, A.A. de Leeuw and M.A. Moerland. Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 82 (4), 1424(2012) 1424-1430. [18] C. Haie-Meder, R. Pötter and E. Van Limbergen. Recommendations from gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV, Radiother Oncol. 74 (3), 235(2005) 67-77. [19] M.J. Rivard, B.M. Coursey and L.A. DeWerd. Update of AAPM Task Group No. 43 Report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys. 31 (3), 633(2004) 633-674. [20] A. Palmer, D. Bradley and A. Nisbet. Physics-aspects of dose accuracy in high dose rate (HDR) brachytherapy: source dosimetry, treatment planning, equipment performance and in vivo verification techniques, J Contemp Brachytherapy. 4 (2), 81(2012) 81-91. [21] K. Asnaashari, S. Gholami and H. Khosravi. Lessons learnt from errors in radiotherapy centers, Iranian J Radiat Res. 12 (4), 361(2014) 361-367. [22] T.P. Hellebust, C Kirisits and D. Berger. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy, Radiother Oncol. 96 (2), 153(2010) 153-160. [23] M. Andrew, Y. Kim and T Ginader. Reduction of applicator displacement in MR/CT-guided cervical cancer HDR brachytherapy by the use of patient hover transport system J Contemp Brachytherapy. 10 (1). 85(2018) 85-90.